10320 Camino Santa Fe, Suite G
San Diego, CA 92121
Tel: 858.875.1900 Fax: 858.875.1999

ADORA2A Antibody (Center) Blocking Peptide

Synthetic peptide
Catalog # BP10467c

Specification

ADORA2A Antibody (Center) Blocking Peptide - Product Information

Primary Accession	P29274
Other Accession	NP_000666.2

ADORA2A Antibody (Center) Blocking Peptide - Additional Information

Gene ID 135

Other Names
Adenosine receptor A2a, ADORA2A, ADORA2

Format
Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

Storage
Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.

Precautions
This product is for research use only. Not for use in diagnostic or therapeutic procedures.

ADORA2A Antibody (Center) Blocking Peptide - Protein Information

Name ADORA2A

Synonyms ADORA2

Function
Receptor for adenosine (By similarity). The activity of this receptor is mediated by G proteins which activate adenylyl cyclase (By similarity).

Cellular Location
Cell membrane {ECO:0000250|UniProtKB:P30543}; Multi-pass membrane protein {ECO:0000250|UniProtKB:P30543} Note=Colocalizes with GAS2L2 at neuronal processes {ECO:0000250|UniProtKB:P30543}

ADORA2A Antibody (Center) Blocking Peptide - Protocols

Provided below are standard protocols that you may find useful for product applications.

- Blocking Peptides

10320 Camino Santa Fe, Suite G
San Diego, CA 92121
Tel: 858.875.1900 Fax: 858.875.1999

ADORA2A Antibody (Center) Blocking Peptide - Images

ADORA2A Antibody (Center) Blocking Peptide - Background

ADORA2A is a protein which is one of severalreceptor subtypes for adenosine. The activity of the encodedprotein, a G-protein coupled receptor family member, is mediated byG proteins which activate adenylyl cyclase. This protein isabundant in basal ganglia, vasculature and platelets and it is amajor target of caffeine.

ADORA2A Antibody (Center) Blocking Peptide - References

Buira, S.P., et al. J. Neurochem. 115(1):283-295(2010)Bailey, S.D., et al. Diabetes Care 33(10):2250-2253(2010)Rogers, P.J., et al. Neuropsychopharmacology 35(9):1973-1983(2010)Tebano, M.T., et al. ScientificWorldJournal 10, 1768-1782 (2010) :Kobayashi, H., et al. Behav Brain Funct 6, 50 (2010) :